8739

The key to knowledge is in your (nitrile-gloved) hands

Already an ACS Member? Log in here

Basic

$0 Community Associate

ACS’s Basic Package keeps you connected with C&EN and ACS.

JOIN NOW

Standard

$80 Regular Members & Society Affiliates

ACS’s Standard Package lets you stay up to date with C&EN, stay active in ACS, and save.

Eligibility restrictions apply. Review ACS Membership Packages to see if you qualify.

JOIN NOW

Premium

$160 Regular Members & Society Affiliates
$55 Graduate Students
$25 Undergraduate Students

ACS’s Premium Package gives you full access to C&EN and everything the ACS Community has to offer.

ACS offers discounts for some countries outside the United States. This discount is shown at checkout, if applicable.

JOIN NOW

« Prev

September 28, 2009 Cover

Volume 87, Issue 39

Drug firms help battle the novel H1N1 virus in response to calls from health agencies and governments

Credit:

Full Article

Volume 87 | Issue 39

« Prev

Drug firms help battle the novel H1N1 virus in response to calls from health agencies and governments

Investment flows into the U.S. as drugmakers reassess their supply chains

Advances in breeding and basic science confer drought tolerance to crops

Biological Chemistry

Targeting RNA

Unique challenges face developers of drugs that hit disease-related RNAs rather than disease-related proteins
Pharmaceuticals

Gaining Focus

Small-molecule drugs to treat dry age-related macular degeneration are heading to the clinic
Pharmaceuticals

Innovators Score

Makers of brand-name biologics get closer to winning 12 years of exclusivity before generic versions can come to market
Sign up for C&EN must-read weekly newsletter

Email Address*

Contact us to opt out anytime